Work

P14.03 Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.08.333

Authors: S. Peters, D.H. Lee, R. Ramlau, B. Halmos, C. Schumann, D. Planchard, N. Bhagwati, Q. Chen, D. Kush, S. Novello

Institutions: Centre Hospitalier Universitaire Vaudois, University of Lausanne, Asan Medical Center, Poznan University of Medical Sciences, Albert Einstein College of Medicine, Montefiore Einstein Comprehensive Cancer Center, Institut Gustave Roussy, Merck & Co., Inc., Rahway, NJ, USA (United States), Ospedale San Luigi Gonzaga, University of Turin

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3205072264

Cites:

Cited by: 3

Related to: 10